Medications for Alcohol Use Disorder: Evidence and Case Examples-Recording - Medications for Alcohol Use Disorder: Evidence and Case Examples

Recording - Medications for Alcohol Use Disorder: Evidence and Case Examples

Video Transcription

Video Summary

Dr. Melissa Wymer, Associate Professor of Medicine and Public Health at Yale, discusses the systematic review of medications for alcohol use disorder (AUD). Addressing the substantial global impact of alcohol, which accounts for approximately 5% of all deaths worldwide, Dr. Wymer highlights the urgent need for effective treatments. In the U.S. alone, alcohol-related deaths far exceed opioid overdoses, with around 178,000 deaths in 2021. Unfortunately, access to medication treatments for AUD remains limited, as fewer than 2% of those affected receive them. <br /><br />Dr. Wymer emphasizes FDA-approved medications like acamprosate, disulfiram, and naltrexone, which reduce cravings and support abstinence. Despite their efficacy, widespread stigma, lack of physician knowledge, and institutional support hinder their usage. While exploring emerging treatments like GLP-1 receptor agonists, Dr. Wymer underscores the importance of optimizing existing medications, supporting patients through care settings, and addressing societal misconceptions. Integrating these treatments into healthcare practices could significantly reduce hospitalizations and mortality, enhancing public health outcomes. Dr. Wymer encourages visiting PCSS MAUD for further educational resources on advancing AUD treatment in clinical settings.

Keywords

Alcohol Use Disorder

Dr. Melissa Wymer

systematic review

FDA-approved medications

acamprosate

disulfiram

naltrexone

GLP-1 receptor agonists

public health